Monotherapy Dose Finding With BI 847325 in Solid Tumours

Summary

The aim of the Phase Ia (dose escalation) part of this trial is to assess the maximum tolerated dose (MTD) of BI 847325 administered at escalating doses in 2 treatment arms. In the Phase Ib expansion part of the trial, the aim is to further evaluate the safety profile of BI 847325 at the recommended dose and schedule and to assess target modulation and the potential antitumour efficacy in patients with selected tumour types.

Timeline

Start

2011-04-15

Primary completion

2013-06-06

Completion

2013-10-10

Drugs

Indications